Dysarthria in individuals with Parkinson's disease: a protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark)

Serge Pinto, Rita Cardoso, Jasmin Sadat, Isabel Guimarães, Céline Mercier, Helena Santos, Cyril Atkinson-Clement, Joana Carvalho, Pauline Welby, Pedro Oliveira, Mariapaola D'Imperio, Sónia Frota, Alban Letanneux, Marina Vigario, Marisa Cruz, Isabel Pavão Martins, François Viallet, Joaquim J Ferreira, Serge Pinto, Rita Cardoso, Jasmin Sadat, Isabel Guimarães, Céline Mercier, Helena Santos, Cyril Atkinson-Clement, Joana Carvalho, Pauline Welby, Pedro Oliveira, Mariapaola D'Imperio, Sónia Frota, Alban Letanneux, Marina Vigario, Marisa Cruz, Isabel Pavão Martins, François Viallet, Joaquim J Ferreira

Abstract

Introduction: Individuals with Parkinson's disease (PD) have to deal with several aspects of voice and speech decline and thus alteration of communication ability during the course of the disease. Among these communication impairments, 3 major challenges include: (1) dysarthria, consisting of orofacial motor dysfunction and dysprosody, which is linked to the neurodegenerative processes; (2) effects of the pharmacological treatment, which vary according to the disease stage; and (3) particular speech modifications that may be language-specific, that is, dependent on the language spoken by the patients. The main objective of the FraLusoPark project is to provide a thorough evaluation of changes in PD speech as a result of pharmacological treatment and disease duration in 2 different languages (French vs European Portuguese).

Methods and analysis: Individuals with PD are enrolled in the study in France (N=60) and Portugal (N=60). Their global motor disability and orofacial motor functions is assessed with specific clinical rating scales, without (OFF) and with (ON) pharmacological treatment. 2 groups of 60 healthy age-matched volunteers provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks are recorded to obtain acoustic and perceptual measures. Patient-reported outcome measures are used to assess the psychosocial impact of dysarthria on quality of life.

Ethics and dissemination: The study has been approved by the local responsible committees on human experimentation and is conducted in accordance with the ethical standards. A valuable large-scale database of speech recordings and metadata from patients with PD in France and Portugal will be constructed. Results will be disseminated in several articles in peer-reviewed journals and in conference presentations. Recommendations on how to assess speech and voice disorders in individuals with PD to monitor the progression and management of symptoms will be provided.

Trial registration number: NCT02753192, Pre-results.

Keywords: Cross-language; Disease progression; Dysarthria; Parkinson’s disease; Pharmacological treatment; Speech.

Conflict of interest statement

Conflicts of Interest: None declared.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Figures

Figure 1
Figure 1
Overview of the FraLusoPark study design. Patient OFF-medication assessments (clinical history, speech recordings and clinical assessments, without medication) are shown in dark grey. ON-medication assessments (speech recordings and clinical assessments after medication are effective) are shown in light grey.

References

    1. Darley FL, Aronson AE, Brown JR. Clusters of deviant speech dimensions in the dysarthrias. J Speech Hear Res 1969;12:462–96. 10.1044/jshr.1203.462
    1. Darley FL, Aronson AE, Brown JR. Differential diagnostic patterns of dysarthria. J Speech Hear Res 1969;12:246–69. 10.1044/jshr.1202.246
    1. Duffy JR. Defining, understanding, and categorizing motor speech disorders. In: Duffy JR, edr. Motor speech disorders—substrates, differential diagnosis, and management. 3rd edn Saint Louis: Elsevier Mosby, 2013:3–13.
    1. Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson's disease and multiple sclerosis: a survey. Folia Phoniatr Logop 1994;46:9–17. 10.1159/000266286
    1. Miller N, Deane KHO, Jones D et al. . National survey of speech and language therapy provision for people with Parkinson's disease in the United Kingdom: therapists’ practices. Int J Lang Commun Disord 2011;46:189–201. 10.3109/13682822.2010.484849
    1. Miller N, Noble E, Jones D et al. . Life with communication changes in Parkinson's disease. Age Ageing 2006;35:235–9. 10.1093/ageing/afj053
    1. Ramig LO, Bonitati CM, Lemke JH et al. . Voice treatment for patients with Parkinson's disease. Development of an approach and preliminary efficacy data. J Med Speech Lang Pathol 1994;2:191–209.
    1. Karlsen KH, Tandberg E, Arsland D et al. . Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatr 2000;69:584–9. 10.1136/jnnp.69.5.584
    1. Fox C, Ramig L. Vocal sound pressure level and self-perception of speech and voice in men and women with idiopathic Parkinson disease. Am J Speech Lang Pathol 1997;2:29–42.
    1. Miller N, Noble E, Jones D et al. . How do I sound to me? Perceived changes in communication in Parkinson's disease. Clin Rehabil 2008;22:14–22.
    1. Barnish MS, Whibley D, Horton SMC et al. . Roles of cognitive status and intelligibility in everyday communication in people Parkinson's disease: a systematic review. J Parkinsons Dis 2016;6:453–62. 10.3233/JPD-150757
    1. Schneider JS, Sendek S, Yang C. Relationship between motor symptoms, cognition, and demographic characteristics in treated mild/moderate Parkinson's disease. PLoS ONE 2015;10:e0123231 10.1371/journal.pone.0123231
    1. Klawans HL. Individual manifestations of Parkinson's disease after ten or more years of levodopa. Mov Disord 1986;1:187–92. 10.1002/mds.870010304
    1. Agid Y, Graybiel AM, Ruberg M et al. . The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? Adv Neurol 1990;53:83–100.
    1. Braak H, Braak E, Yilmazer D et al. . Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl 1995;46:15–31.
    1. Halliday G, Lees A, Stern M. Milestones in Parkinson's disease—clinical and pathologic features. Mov Disord 2011;26:1015–21. 10.1002/mds.23669
    1. Ho AK, Bradshaw JL, Iansek R et al. . Speech volume regulation in Parkinson's disease: effects of implicit cues and explicit instructions. Neuropsychologia 1999;37:1453–60. 10.1016/S0028-3932(99)00067-6
    1. Pinto S, Ozsancak C, Tripoliti E et al. . Treatments for dysarthria in Parkinson's disease. Lancet Neurol 2004;3:547–56. 10.1016/S1474-4422(04)00854-3
    1. Atkinson-Clement C, Sadat J, Pinto S. Behavioral treatments for speech in Parkinson's disease: meta-analyses and review of the literature. Neurodegener Dis Manag 2015;5:233–48. 10.2217/nmt.15.16
    1. Patel R. Assessment of prosody. In: Lowit A, Kent R, eds. Assessment of motor speech disorders. San Diego: Plural Publishing, 2011:75–96.
    1. Viallet F, Meynadier Y, Lagrue B et al. . The reductions of tonal range and of average pitch during speech production in “off” parkinsonians are restored by L-DOPA. Mov Disord 2000;15:S131.
    1. Cheang HS, Pell MD. An acoustic investigation of Parkinsonian speech in linguistic and emotional contexts. J Neurolinguistics 2007;20:221–41. 10.1016/j.jneuroling.2006.07.001
    1. Hammen VL, Yorkston KM. Speech and pause characteristics following speech rate reduction in hypokinetic dysarthria. J Comm Disord 1996;29:429–44. 10.1016/0021-9924(95)00037-2
    1. Duez D. Organisation temporelle de la parole et dysarthrie parkinsonienne. In: Ozsancak C, Auzou P, eds. Les troubles de la parole et de la déglutition dans la maladie de Parkinson. Marseille: Solal, 2005:195–211.
    1. Duez D. Segmental duration in Parkinsonian French speech. Folia Phoniatr Logop 2009;61:239–46. 10.1159/000228001
    1. Rigrodsky S, Morrison EB. Speech changes in parkinsonism during L-dopa therapy: preliminary findings. J Am Geriatr Soc 1970;18:142–51. 10.1111/j.1532-5415.1970.tb02111.x
    1. Mawdsley C, Gamsu CV. Periodicity of speech in Parkinsonism. Nature 1971;231:315–16. 10.1038/231315a0
    1. Leanderson R, Meyerson BA, Persson A. Effect of L-dopa on speech in Parkinsonism. An EMG study of labial articulatory function. J Neurol Neurosurg Psychiatry 1971;34:679–81. 10.1136/jnnp.34.6.679
    1. Nakano KK, Zubick H, Tyler HR. Speech defects of parkinsonian patients. Effects of levodopa therapy on speech intelligibility. Neurology 1973;23:865–70.
    1. Ferreira JJ, Rascol O, Poewe W et al. . A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease. CNS Neurosci Ther 2010;16:337–47. 10.1111/j.1755-5949.2010.00145.x
    1. Mestre T, Ferreira JJ. Pharmacotherapy in Parkinson's disease: case studies. Ther Adv Neurol Disord 2010;3:117–26. 10.1177/1756285609352366
    1. Wolfe VI, Garvin JS, Bacon M et al. . Speech changes in Parkinson's disease during treatment with L-dopa. J Commun Disord 1975;8:271–9. 10.1016/0021-9924(75)90019-2
    1. Quaglieri CE, Celesia GG. Effect of thalamotomy and levodopa therapy on the speech of Parkinson patients. Eur Neurol 1977;15:34–9. 10.1159/000114786
    1. Marsden CD, Parkes JD. “On-off” effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292–6. 10.1016/S0140-6736(76)91416-1
    1. Critchley EM. Letter: peak-dose dysphonia in parkinsonism. Lancet 1976;1:544 10.1016/S0140-6736(76)90337-8
    1. De Letter M, Santens P, De Bodt M et al. . The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease. Clin Neurol Neurosurg 2007;109:495–500. 10.1016/j.clineuro.2007.04.003
    1. De Letter M, Santens P, Estercam I et al. . Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners. Clin Linguist Phon 2007;21:783–91. 10.1080/02699200701538181
    1. Skodda S, Visser W, Schlegel U. Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease. J Neural Transm (Vienna) 2010;117:197–205. 10.1007/s00702-009-0351-5
    1. Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol 2012;8:435–42. 10.1038/nrneurol.2012.126
    1. Goberman A, Coelho C, Robb M. Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states. J Commun Disord 2002;35:217–39. 10.1016/S0021-9924(01)00072-7
    1. Goberman AM, Blomgren M. Parkinsonian speech disfluencies: effects of L-dopa-related fluctuations. J Fluency Disord 2003;28:55–70. 10.1016/S0094-730X(03)00005-6
    1. Pinto S, Gentil M, Krack P et al. . Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech. Mov Disord 2005;20:1507–15. 10.1002/mds.20601
    1. Skodda S, Flasskamp A, Schlegel U. Instability of syllable repetition in Parkinson's disease—influence of levodopa and deep brain stimulation. Mov Disord 2011;26:728–30. 10.1002/mds.23439
    1. Skodda S, Grönheit W, Schlegel U. Intonation and speech rate in Parkinson's disease: general and dynamic aspects and responsiveness to levodopa admission. J Voice 2011;25:e199–205. 10.1016/j.jvoice.2010.04.007
    1. Ladd R. Intonational phonology. Cambridge: Cambridge University Press, 1996.
    1. Frota S. Nuclear falls and rises in European Portuguese: a phonological analysis of declarative and question intonation. Probus 2002;14:113–46. 10.1515/prbs.2002.001
    1. Frota S. The intonational phonology of European Portuguese. In: Jun SA, edr. Prosodic typology II. The phonology of intonation and phrasing, chapter 2. Oxford: Oxford University Press, 2014:6–42.
    1. Welby P. The role of early fundamental frequency rises and elbows in French word segmentation. Speech Commun 2007;49:28–48. 10.1016/j.specom.2006.10.005
    1. Cruz-Ferreira M. Intonation in European Portuguese. In: Hirst D, Di Cristo A, eds. Intonation systems. a survey of twenty languages. Cambridge: Cambridge University Press, 1998:167–78.
    1. Cruz-Ferreira M. Part 2: Illustrations of the IPA. Portuguese (European). In: Handbook of the International Phonetic Association. A guide to the use of the International Phonetic Alphabet. Cambridge: Cambridge University Press, 1999:126–30.
    1. Frota S. Prosody and focus in European Portuguese. Phonological phrasing and intonation. New York: Garland Publishing, 2000.
    1. Jun SA, Fougeron C. Realizations of accentual phrase in French. Probus 2002;14:147–72.
    1. Welby P. French intonational structure: evidence from tonal alignment. J Phonetics 2006;34:343–71. 10.1016/j.wocn.2005.09.001
    1. Spinelli E, Grimault N, Meunier F et al. . An intonational cue to word segmentation in phonemically identical sequences. Atten Percept Psychophys 2010;72:775–87. 10.3758/APP.72.3.775
    1. Ma JK, Whitehill TL, So SY. Intonation contrast in Cantonese speakers with hypokinetic dysarthria associated with Parkinson's disease. J Speech Lang Hear Res 2010;53:836–49. 10.1044/1092-4388(2009/08-0216)
    1. Whitehill TL. Studies of Chinese speakers with dysarthria: informing theoretical models. Folia Phoniatr Logop 2010;62:92–6. 10.1159/000287206
    1. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatr 1988;51:745–52. 10.1136/jnnp.51.6.745
    1. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971;9:97–113. 10.1016/0028-3932(71)90067-4
    1. Enderby P, Palmer R. Frenchay Dysarthria Assessment. (FDA-2). 2nd edn Austin, TX: Pro-ED, 2007.
    1. Fougeron C, Smith CL. Part 2: illustrations of the IPA. French. In: Handbook of the International Phonetic Association. A guide to the use of the International Phonetic Alphabet. Cambridge: Cambridge University Press, 1999:78–81.
    1. Mayer M. Frog, where are you? Sequel to a boy, a dog and a frog. New-York: Dial books, 1969.
    1. Berman RA, Slobin DI. Relating events in narrative: a crosslinguistic developmental study. Hillsdale, NJ: Lawrence Erlbaum Associates,1994.
    1. Baken RJ, Orlikoff RF. Clinical measurement of speech and voice. San Diego: Singular Publishing Group Inc, 2000.
    1. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent developments in Parkinson's disease, Vol. 2. Florham Park: MacMillan Health Care Information, 1987:153–64.
    1. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738–50. 10.1002/mds.10473
    1. Nasreddine ZS, Phillips NA, Bédirian V et al. . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–9. 10.1111/j.1532-5415.2005.53221.x
    1. Busner J, Targum SD. The Clinical Global Impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007;4:28–37.
    1. Walshe M, Peach RK, Miller N. Dysarthria impact profile: development of a scale to measure psychosocial effects. Int J Lang Com Disord 2009;44:693–715. 10.1080/13682820802317536
    1. Walshe M. The psychosocial impact of acquired motor speech disorders. In: Lowit A, Kent RD, eds. Assessment of motor speech disorders. San Diego: Plural Publishing Inc, 2011:97–122.
    1. Jenkinson C, Peto V, Fitzpatrick R et al. . Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39). Age Ageing 1995;24:505–9. 10.1093/ageing/24.6.505
    1. Peto V, Jenkinson C, Fitzpatrick R et al. . The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995;4:241–8. 10.1007/BF02260863
    1. Jacobson BH, Johnson A, Grywalski C et al. . The Voice Handicap Index (VHI), development and validation. Am J Speech Pathol 1997;6:66–70. 10.1044/1058-0360.0603.66
    1. Letanneux A, Viallet F, Walshe M et al. . The Dysarthria Impact Profile: a preliminary French experience with Parkinson's disease. Parkinsons Dis 2013;2013:403680 10.1155/2013/403680
    1. Guimarães I, Abberton E. An investigation of the Voice Handicap Index with speakers of Portuguese: preliminary data. J Voice 2004;18:71–82. 10.1016/j.jvoice.2003.07.002
    1. Woisard V, Bodin S, Puech M. [The Voice Handicap Index: impact of the translation in French on the validation]. Rev Laryngol Otol Rhinol 2004;125:307–12.
    1. Auquier P, Sapin C, Ziegler M et al. . [Validation of the French language version of the Parkinson's Disease Questionnaire—PDQ-39]. Rev Neurol (Paris) 2002;158:41–50.
    1. Souza RG, Borges V, Silva SM et al. . Quality of life scale in Parkinson's disease PDQ-39 (Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation. Arq Neuro Psiq 2007;65:787–91. 10.1590/S0004-282X2007000500010
    1. Vieira EM. Qualidade de vida na doença de Parkinson. Ph.D. thesis. Faculdade de Medicina da Universidade de Coimbra 2008.
    1. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther 2004;27:26–3. 10.1016/j.jmpt.2003.11.003
    1. Beck AT, Ward CH, Mendelson M et al. . An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–71. 10.1001/archpsyc.1961.01710120031004
    1. D'Imperio M. Prosodic representations (section on tonal alignment). In: Cohn A, Fougeron C, Huffman M, eds. The Oxford Handbook of Laboratory Phonology. Oxford: Oxford University Press, 2011:275–87.
    1. Welby P, Lœvenbruck H. Anchored down in anchorage: syllable structure and segmental anchoring in French. Italian J Ling 2006;18:74–124.
    1. Frota S. Tonal association and target alignment in European Portuguese nuclear falls. In: Gussenhoven C, Warner N, eds. Laboratory phonology 7. Berlin/New York: Mouton de Gruyter, 2002:387–418.
    1. Martínez-Martin P. An introduction to the concept of “quality of life in Parkinson's disease”. J Neurol 1998;245:S2–6. 10.1007/PL00007733
    1. Kuopio AM, Marttila RJ, Helenius H et al. . The quality of life in Parkinson's disease. Mov Disord 2000;15:216–23.
    1. World Medical Association. 59th General Assembly. Seoul, Korea: World Medical Association, 2008.
    1. Ghio A, Pouchoulin G, Teston B et al. . How to manage sound, physiological and clinical data of 2500 dysphonic and dysarthric speakers? Speech Commun 2012;54:664–79. 10.1016/j.specom.2011.04.002
    1. World Health Organisation (WHO). International Classification of Functioning (ICF), Disability and Health. Geneva, Switzerland: World Health Organisation, 2001.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel